Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:3787895rdf:typepubmed:Citationlld:pubmed
pubmed-article:3787895lifeskim:mentionsumls-concept:C0022650lld:lifeskim
pubmed-article:3787895lifeskim:mentionsumls-concept:C0178602lld:lifeskim
pubmed-article:3787895lifeskim:mentionsumls-concept:C0596545lld:lifeskim
pubmed-article:3787895lifeskim:mentionsumls-concept:C0205251lld:lifeskim
pubmed-article:3787895lifeskim:mentionsumls-concept:C0205210lld:lifeskim
pubmed-article:3787895lifeskim:mentionsumls-concept:C0072188lld:lifeskim
pubmed-article:3787895pubmed:issue5lld:pubmed
pubmed-article:3787895pubmed:dateCreated1986-12-19lld:pubmed
pubmed-article:3787895pubmed:abstractTextThe use of drugs inhibiting bacterial urease represents an interesting improvement in preventive treatment of renal infected stones. The low dose (120 mg/day) for one week followed by 60 mg/day of propionohydroxamic acid (PHA) has shown excellent anti-urease activity. The nearly normal absence of side effects also allows long-term administration.lld:pubmed
pubmed-article:3787895pubmed:languageenglld:pubmed
pubmed-article:3787895pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3787895pubmed:citationSubsetIMlld:pubmed
pubmed-article:3787895pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3787895pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3787895pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3787895pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3787895pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3787895pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3787895pubmed:statusMEDLINElld:pubmed
pubmed-article:3787895pubmed:monthNovlld:pubmed
pubmed-article:3787895pubmed:issn0090-4295lld:pubmed
pubmed-article:3787895pubmed:authorpubmed-author:BullSSlld:pubmed
pubmed-article:3787895pubmed:authorpubmed-author:MartelliAAlld:pubmed
pubmed-article:3787895pubmed:authorpubmed-author:SpataforaSSlld:pubmed
pubmed-article:3787895pubmed:issnTypePrintlld:pubmed
pubmed-article:3787895pubmed:volume28lld:pubmed
pubmed-article:3787895pubmed:ownerNLMlld:pubmed
pubmed-article:3787895pubmed:authorsCompleteYlld:pubmed
pubmed-article:3787895pubmed:pagination373-5lld:pubmed
pubmed-article:3787895pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:3787895pubmed:meshHeadingpubmed-meshheading:3787895-...lld:pubmed
pubmed-article:3787895pubmed:meshHeadingpubmed-meshheading:3787895-...lld:pubmed
pubmed-article:3787895pubmed:meshHeadingpubmed-meshheading:3787895-...lld:pubmed
pubmed-article:3787895pubmed:meshHeadingpubmed-meshheading:3787895-...lld:pubmed
pubmed-article:3787895pubmed:meshHeadingpubmed-meshheading:3787895-...lld:pubmed
pubmed-article:3787895pubmed:meshHeadingpubmed-meshheading:3787895-...lld:pubmed
pubmed-article:3787895pubmed:meshHeadingpubmed-meshheading:3787895-...lld:pubmed
pubmed-article:3787895pubmed:year1986lld:pubmed
pubmed-article:3787895pubmed:articleTitleClinical experience with low dosage of propionohydroxamic acid (PHA) in infected renal stones.lld:pubmed
pubmed-article:3787895pubmed:publicationTypeJournal Articlelld:pubmed